The Developmental Effects of Environmental Enrichment on the Minor Cannabinoid Drug Reward and Cannabinoid Receptor Levels
Project Number1R15DA058811-01
Contact PI/Project LeaderSTAIRS, DUSTIN JEFFREY
Awardee OrganizationCREIGHTON UNIVERSITY
Description
Abstract Text
Project Summary/Abstract
Understanding individual differences in the vulnerability to drug abuse is an important component to developing
better prevention and treatment strategies. Evidence indicates that personality traits such as “novelty-seeking”
or “sensation-seeking” can influence drug use. The rodent environmental enrichment paradigm has been
shown to reliably induce a behavioral phenotype that models the increased drug abuse vulnerability seen with
the novelty-seeking personality trait. In this enrichment model, rats are raised in environments with either high
or low levels of novelty throughout early adolescence and through adulthood. Rats exposed to high levels of
novelty (enriched rats) are consistently found to be less sensitive to low doses of various drugs of abuse
compared to rats exposed to low levels of novelty (impoverished rats) when tested in young adulthood. When
using this model, the altered sensitivity to drugs of abuse is traditionally not tested until the animals reach
adulthood. A more systematic investigation on when during adolescence exposure to high- or low-novelty
environments induces these altered behavioral phenotypes is warranted. This may be particularly important as
the peak of when people initiate cannabis use is during adolescence. Given the popularity of cannabinoid
drugs, it is surprising that there is little to no research investigating whether environmental enrichment can alter
sensitivity to marijuana. While delta-9-Tetrahydrocannabinol (delta-9-THC) is considered the major
psychoactive ingredient of marijuana, the passage of the 2018 “Farm Bill” has led to the rise in the popularity of
minor cannabinoids of the hemp plant including delta-8-Tetrahydrocannabinol (delta-8-THC) and cannabidiol
(CBD). Products containing delta-8-THC have recently skyrocketed in popularity, particularly in states where
delta-9-THC remains fully illegal. A main goal of the proposed research is to combine new research from our
lab looking at the abuse liability of vaped or pulmonary administration of delta-8-THC and CBD and
combinations of these compounds using a conditioned place preference (CPP) procedure and determine when
and if adolescent environmental enrichment exposure can alter the sensitivity to these cannabis drugs. A
second goal is to determine when and if adolescent environmental enrichment exposure may alter brain
cannabinoid receptor densities in key brain structures involved in the rewarding and behavioral effects of
cannabinoid drugs.
Public Health Relevance Statement
Project Narrative
While the rodent environmental enrichment model has been shown to be protective against various drugs of
abuse, the developmental onset of this enrichment has not been elucidated nor have the effects of enrichment
on cannabinoid drugs been investigated. The purpose of this study is to determine if the length of exposure to
environmental enrichment during adolescence differentially alters brain density of the cannabinoid receptors
(CB1R) or the rewarding effects of vaped delta-8 tetrahydrocannabinol, cannabidiol, and mixtures of these
compounds. The results of the current proposal will be important in determining whether enrichment during
development protects against the rewarding effects of popular vaped cannabinoids.
No Sub Projects information available for 1R15DA058811-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R15DA058811-01
Patents
No Patents information available for 1R15DA058811-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R15DA058811-01
Clinical Studies
No Clinical Studies information available for 1R15DA058811-01
News and More
Related News Releases
No news release information available for 1R15DA058811-01
History
No Historical information available for 1R15DA058811-01
Similar Projects
No Similar Projects information available for 1R15DA058811-01